pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
KEYTRUDA · news · pharmadog
← back to KEYTRUDA
News mentioning KEYTRUDA
219
stories
15h
Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns
biospace
17h
Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety
biospace
2d
Sellas marks 9-month survival benefit in late-stage leukemia vaccine study
fiercebiotech
2d
Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
biopharma dive
3d
Summit's PD-1xVEGF rejected by FDA in lung cancer
biospace
5d
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
fiercebiotech
6d
BMS R&D head to depart amid restructure
biospace
7d
BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’
fiercebiotech
8d
Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rival
biospace
9d
AbCellera becomes latest biotech to abandon dream of developing OX40 drug
fiercebiotech
9d
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
biospace
11d
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
fiercebiotech
12d
Moderna enjoys stable vaccine sales thanks to global COVID uptake
biospace
12d
Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November
biospace
12d
Merck, Moderna serve 99% of trial patients with mRNA vaccine as personalized shots near market
biospace
12d
Moderna’s norovirus vaccine plans in limbo in wake of phase 3 miss
fiercebiotech
13d
Faeth’s phase 2 data power oral combo forward in cancer targeted by ADC heavyweights
fiercebiotech
13d
Merck abandons Sutro-partnered IL-2 drug in ‘routine pipeline prioritization’
fiercebiotech
13d
Revolution’s Rasonque off to best cancer drug launch ‘in history’
biopharma dive
15d
6 potential blockbusters that could pave China’s path to 2030 ambitions
biospace
15d
AbbVie abandons phase 2 solid tumor drug over ‘limited benefit’
fiercebiotech
16d
Keytruda biosimilars are coming — but they face an uphill battle
biopharma dive
16d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
19d
This week in charts: ESMO’s winners and losers
biopharma dive
20d
Genmab soars to record highs after cancer drug succeeds in key trial
biopharma dive
20d
Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms
biospace
20d
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
biospace
20d
Merck outlines 2027 as ‘another year of investment’ despite recent clinical wins
fiercebiotech
21d
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
biospace
21d
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
biospace
← prev
page 1 of 8
next →